NCT00919477已完成不适用
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 712
- 试验地点
- 1
- 主要终点
- Adverse event incidence
研究概览
简要总结
To gather information on the safety of monotherapy of Casodex® tablets 80 mg, targeting prostate cancer patients who have no history of having received treatment by either endocrine therapy (including surgical castration).
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Prostate cancer patients who have no history of receiving endocrine therapy (including surgical castration), and who plan to undergo Casodex® tablets monotherapy for not less than 12 months
排除标准
- 未提供
结局指标
主要结局
Adverse event incidence
时间窗: Time since starting Casodex monotherapy, monthly
次要结局
- improvement of prostate cancer using Tumor marker PSA(Time since starting Casodex monotherapy, monthly)
- Maintenance of sexual function(At 3 months since starting Casodex monotherapy,)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Clinical Evaluation of ExoDx Prostate(IntelliScore) in Men Presenting for Initial Prostate BiopsyUrologic CancerNCT04720599Exosome Diagnostics, Inc.120
已完成
3 期
CORETOX® in Treatment of Post Stroke Upper Limb Spasticity (Phase3)Muscle SpasticityNCT03289702Medy-Tox220
已完成
1 期
Single Dose Study of MK-2060 to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Older Japanese Participants on Dialysis (MK-2060-012)End-Stage Renal Disease (ESRD)End-Stage Kidney Disease (ESKD)Kidney Failure, ChronicNCT05769595Merck Sharp & Dohme LLC17
已完成
1 期
CORETOX® in Treatment of Post Stroke Upper Limb Spasticity (Phase1)Muscle SpasticityNCT05164003Medy-Tox30
终止
1 期
Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPCMetastatic Castration-resistant Prostate CancerProstate CancerNCT03792841Amgen212